OBJECTIVE: To investigate the risk for language impairment (LI) in children perinatally infected or exposed to HIV. METHODS: We evaluated the prevalence of LI in 7- to 16-year-old children with perinatal HIV infection (HIV+) compared with HIV-exposed and uninfected children, using a comprehensive standardized language test (Clinical Evaluation of Language Functioning-Fourth Edition [CELF-4]). LI was classified as primary LI (Pri-LI) (monolingual English exposure and no cognitive or hearing impairment), concurrent LI (Con-LI) (cognitive or hearing impairment), or no LI. Associations of demographic, caregiver, HIV disease, and antiretroviral treatment factors with LI category were evaluated using univariate and multivariable logistic regression models. RESULTS: Of the 468 children with language assessments, 184 (39%) had LI. No difference was observed by HIV infection status for overall LI or for Pri-LI or Con-LI; mean (SD) CELF-4 scores were 88.5 (18.4) for HIV+ versus 87.5 (17.9) for HIV-exposed and uninfected children. After adjustment, black children had higher odds of Pri-LI versus no LI (adjusted odds ratio [aOR] = 2.43, p = .03). Children who were black, Hispanic, had a caregiver with low education or low intelligence quotient, or a nonbiological parent as caregiver had higher odds of Con-LI versus no LI. Among HIV+ children, viral load >400 copies/mL (aOR = 3.04, p < .001), Centers for Disease Control and Prevention Class C (aOR = 2.19, p = .02), and antiretroviral treatment initiation <6 months of age (aOR = 2.12, p = .02) were associated with higher odds of Con-LI versus no LI. CONCLUSIONS: Children perinatally exposed to HIV are at high risk for LI, but such risk was not increased for youth with HIV. Risk factors differed for Pri-LI and Con-LI.
OBJECTIVE: To investigate the risk for language impairment (LI) in children perinatally infected or exposed to HIV. METHODS: We evaluated the prevalence of LI in 7- to 16-year-old children with perinatal HIV infection (HIV+) compared with HIV-exposed and uninfected children, using a comprehensive standardized language test (Clinical Evaluation of Language Functioning-Fourth Edition [CELF-4]). LI was classified as primary LI (Pri-LI) (monolingual English exposure and no cognitive or hearing impairment), concurrent LI (Con-LI) (cognitive or hearing impairment), or no LI. Associations of demographic, caregiver, HIV disease, and antiretroviral treatment factors with LI category were evaluated using univariate and multivariable logistic regression models. RESULTS: Of the 468 children with language assessments, 184 (39%) had LI. No difference was observed by HIV infection status for overall LI or for Pri-LI or Con-LI; mean (SD) CELF-4 scores were 88.5 (18.4) for HIV+ versus 87.5 (17.9) for HIV-exposed and uninfected children. After adjustment, black children had higher odds of Pri-LI versus no LI (adjusted odds ratio [aOR] = 2.43, p = .03). Children who were black, Hispanic, had a caregiver with low education or low intelligence quotient, or a nonbiological parent as caregiver had higher odds of Con-LI versus no LI. Among HIV+ children, viral load >400 copies/mL (aOR = 3.04, p < .001), Centers for Disease Control and Prevention Class C (aOR = 2.19, p = .02), and antiretroviral treatment initiation <6 months of age (aOR = 2.12, p = .02) were associated with higher odds of Con-LI versus no LI. CONCLUSIONS:Children perinatally exposed to HIV are at high risk for LI, but such risk was not increased for youth with HIV. Risk factors differed for Pri-LI and Con-LI.
Authors: Marilyn J Crain; Miriam C Chernoff; James M Oleske; Susan B Brogly; Kathleen M Malee; Peggy R Borum; William A Meyer; Wendy G Mitchell; John H Moye; Heather M Ford-Chatterton; Russell B Van Dyke; George R Seage Iii Journal: J Infect Dis Date: 2010-07-15 Impact factor: 5.226
Authors: M Falcaro; A Pickles; D F Newbury; L Addis; E Banfield; S E Fisher; A P Monaco; Z Simkin; G Conti-Ramsden Journal: Genes Brain Behav Date: 2007-11-12 Impact factor: 3.449
Authors: C J Johnson; J H Beitchman; A Young; M Escobar; L Atkinson; B Wilson; E B Brownlie; L Douglas; N Taback; I Lam; M Wang Journal: J Speech Lang Hear Res Date: 1999-06 Impact factor: 2.297
Authors: C Raskino; D A Pearson; C J Baker; M H Lifschitz; K O'Donnell; M Mintz; M Nozyce; P Brouwers; R E McKinney; E Jimenez; J A Englund Journal: Pediatrics Date: 1999-09 Impact factor: 7.124
Authors: Sarah K Himes; Yanling Huo; George K Siberry; Paige L Williams; Mabel L Rice; Patricia A Sirois; Toni Frederick; Rohan Hazra; Marilyn A Huestis Journal: J Acquir Immune Defic Syndr Date: 2015-06-01 Impact factor: 3.731
Authors: Heena Brahmbhatt; Michael Boivin; Victor Ssempijja; Godfrey Kigozi; Joseph Kagaayi; David Serwadda; Ronald H Gray Journal: J Acquir Immune Defic Syndr Date: 2014-11-01 Impact factor: 3.731
Authors: Mabel L Rice; Jonathan S Russell; Toni Frederick; Murli Purswani; Paige L Williams; George K Siberry; Sean M Redmond; Howard J Hoffman; Tzy-Jyun Yao Journal: Pediatr Infect Dis J Date: 2018-07 Impact factor: 2.129
Authors: Sean M Redmond; Tzy-Jyun Yao; Jonathan S Russell; Mabel L Rice; Howard J Hoffman; George K Siberry; Toni Frederick; Murli Purswani; Paige L Williams Journal: J Pediatric Infect Dis Soc Date: 2016-12 Impact factor: 3.164
Authors: Sarah K Himes; Karl B Scheidweiler; Katherine Tassiopoulos; Deborah Kacanek; Rohan Hazra; Kenneth Rich; Marilyn A Huestis Journal: Anal Chem Date: 2013-01-14 Impact factor: 6.986
Authors: Nicole Phillips; Taryn Amos; Caroline Kuo; Jacqueline Hoare; Jonathan Ipser; Kevin G F Thomas; Dan J Stein Journal: Pediatrics Date: 2016-10-11 Impact factor: 7.124